Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine Oct 12, 2021 8:23am EDT
Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021 Sep 02, 2021 8:45am EDT
Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait Jul 15, 2021 9:00am EDT
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program Jun 15, 2021 11:21am EDT
Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug Authority May 26, 2021 12:19pm EDT
Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review May 04, 2021 9:30am EDT
